Novartis Acquires UK Biotech Firm Myricx Bio for $1.5 Billion

Swiss pharmaceutical giant Novartis has signed an agreement to acquire UK-based biotechnology company Myricx Bio, which specializes in next-generation cancer treatments. The total value of the deal has been announced as $1.5 billion. Myricx Bio is known for its expertise in developing targeted cancer drugs. Novartis aims to strengthen its oncology portfolio and gain access to new therapeutic approaches through this acquisition. Under the agreement, Novartis will incorporate Myricx Bio's existing drug candidates and research platform. This move is expected to accelerate Novartis' R&D efforts in the cancer field. The acquisition is projected to be completed within 2025, following regulatory approvals. Novartis officials stated that the deal will make a significant contribution to the company's long-term growth strategy. This is not investment advice.

📊 NVS — Piyasa Yorumu

▲ up · 60%

The news can be perceived as a positive step for Novartis's growth strategy and may provide short-term support for the stock. Technical indicators also point to a strong upward trend; although the RSI at 68 is approaching overbought territory, the MACD remains above the signal line and is positive. The price is trading above the 20- and 50-day moving averages, indicating continued upward momentum. However, caution is warranted due to the high acquisition cost and integration risks. Short-term upside potential exists, but excessive optimism should be avoided.

RSI 14

67.9

MACD

1.04

24h Δ

1.95%

Canlı Grafikler